Pennant Investors LP Acquires New Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Pennant Investors LP bought a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAFree Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 35,100 shares of the biotechnology company’s stock, valued at approximately $330,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quantbot Technologies LP boosted its position in Enanta Pharmaceuticals by 2,300.0% during the third quarter. Quantbot Technologies LP now owns 7,200 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 6,900 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth approximately $698,000. Clearstead Advisors LLC bought a new position in shares of Enanta Pharmaceuticals during the 3rd quarter worth approximately $57,000. Acadian Asset Management LLC lifted its position in Enanta Pharmaceuticals by 445.6% during the third quarter. Acadian Asset Management LLC now owns 548,782 shares of the biotechnology company’s stock valued at $6,125,000 after acquiring an additional 448,201 shares during the last quarter. Finally, Trexquant Investment LP acquired a new stake in Enanta Pharmaceuticals in the third quarter valued at approximately $1,481,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ENTA. JMP Securities reduced their price target on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating on the stock in a research report on Tuesday, May 7th. StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. Finally, HC Wainwright cut their price objective on shares of Enanta Pharmaceuticals from $28.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $19.00.

Get Our Latest Stock Report on ENTA

Enanta Pharmaceuticals Stock Performance

Shares of Enanta Pharmaceuticals stock traded up $0.30 during trading on Tuesday, hitting $13.08. 58,863 shares of the company’s stock were exchanged, compared to its average volume of 227,278. The stock has a market capitalization of $277.02 million, a price-to-earnings ratio of -2.08 and a beta of 0.57. The business has a 50-day simple moving average of $13.66 and a 200-day simple moving average of $12.70. Enanta Pharmaceuticals, Inc. has a 52-week low of $8.08 and a 52-week high of $26.58.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Free Report) last released its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.21). Enanta Pharmaceuticals had a negative net margin of 180.76% and a negative return on equity of 64.85%. The company had revenue of $17.05 million for the quarter, compared to analysts’ expectations of $16.47 million. On average, equities analysts anticipate that Enanta Pharmaceuticals, Inc. will post -5.95 earnings per share for the current fiscal year.

About Enanta Pharmaceuticals

(Free Report)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

Further Reading

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAFree Report).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.